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Pancreatic cancer is one of the most devastating human malignancies. Despite considerable research efforts, it remains resistant to
almost all available treatment regimens. The human trophoblast cell-surface antigen, TROP2, was found to be strongly expressed in a
variety of human epithelial cancers, correlating with aggressiveness and poor prognosis. TROP2 antigen expression was investigated
retrospectively by immunohistochemistry in paraffin-embedded primary tumour tissue samples from a series (n¼197) of consecutive
patients with pancreatic adenocarcinoma. Survival was calculated using Kaplan–Meier curves. Parameters found to be of prognostic
significance in univariate analysis were verified in a multivariate Cox regression model. TROP2 overexpression was observed in 109
(55%) of 197 pancreatic cancer patients and was significantly associated with decreased overall survival (Po0.01). By univariate
analysis, TROP2 overexpression was found to correlate with the presence of lymph node metastasis (P¼0.04) and tumour grade
(P¼0.01). Furthermore, in the subgroup of patients treated surgically with curative intent, TROP2 overexpression significantly
correlated with poor progression-free survival (Po0.01). Multivariate analyses revealed TROP2 to be an independent prognosticator.
These findings suggest for the first time that TROP2 could be a novel prognostic biomarker for pancreatic cancer. Targeting TROP2
might be a useful treatment approach for patients with pancreatic cancer overexpressing this cell-surface marker.
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Pancreatic cancer is a fatal disorder. At the time of diagnosis, most
patients already have locally advanced or metastatic disease
excluding surgical resection (Yeo et al, 1997). Treatment regimens
followed at present are ineffective and do not prolong patient
survival significantly. Survival rates for the 15–20% of patients
who have resectable disease at first presentation are disappointing,
depending on the status of resection margins and surrounding
lymph nodes. Moreover, the prognosis is poor even for those who
undergo complete (R0) resection. The 5-year overall survival
rate for all stages is approximately 5%, whereas after radical
pancreaticoduodenectomy it has been reported to range from 25 to
30% (Sohn et al, 2000; Jemal et al, 2005). To date, there are no
validated prognostic indicators for identifying patients with non-
metastatic disease and good or poor prognosis. As a consequence,
there is an urgent need for novel prognostic biomarkers as well as
for therapeutic target structures in pancreatic cancer.
In the past, we found GA733-encoded proteins (EpCAM,
TROP2) to be prognostic for a variety of epithelial cancers (Gastl
et al, 2000; Varga et al, 2004; Fong et al, 2008). GA733 is a member
of a family of at least two closely related genes (GA733-1; TACSTD2
and GA733-2; TACSTD1) that share sequence homology with both
thyroglobulin type I and interleukin-2 receptors. The integral
glycoprotein EpCAM is encoded by the GA733-2 gene functions as
a homotypic intercellular adhesion molecule (Litvinov et al, 1994),
and has been targeted by antibody-mediated immunotherapy
(Riethmuller et al, 1998; Ruan et al, 2003).
The human trophoblast cell-surface antigen, TROP2 (also
termed GA733-1), is a transmembrane glycoprotein found to be
expressed at high levels by various types of human carcinomas
(Fradet et al, 1984; Stein et al, 1993a; Nakashima et al, 2004). In
contrast, normal epithelial tissues show little or no TROP2
expression (Stein et al, 1993a; Zhang et al, 1997). TROP2 is
encoded by the GA733-1 gene, which is intronless, formed by
exon-shuffling and retroposition of the GA733-2 gene through
mRNA intermediate (Linnenbach et al, 1993). Recently, TROP2
antigen expression in colorectal and squamous cell carcinomas of
the oral cavity was shown to correlate with tumour aggressiveness
and poor prognosis (Ohmachi et al, 2006; Fong et al, 2008).
Moreover, Wang et al (2008) were able to identify TROP2 as an
oncogene and an attractive therapeutic target in colon cancer.
These findings indicate a potential role for TROP2 in tumour
development and progression. In this retrospective study, we
evaluated TROP2 antigen expression and its correlation with
clinicopathologic features in pancreatic cancer.
MATERIALS AND METHODS
Patients and tissue samples
This study was conducted according to the regulations of the local
Ethics Committee and Austrian law. A total number of 197
consecutive patients with pancreatic ductal adenocarcinoma, from
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swhom formalin-fixed, paraffin-embedded tissue samples were
available, diagnosed between 1990 and 2006 at the Department
of Pathology, Innsbruck Medical University, were included in this
retrospective study. Patients with other pancreatic malignancies,
such as intraductal papillary mucinous adenocarcinoma, acinar
cell carcinoma and malignant endocrine tumours, were excluded.
All tumour specimens were reclassified on hematoxylin-and-eosin-
stained slides, and histological type and tumour grade were
reassessed by a pathologist (PM) using standard diagnostic
criteria. Clinical data were obtained by reviewing the charts and
contacting the physicians in charge. Tumours were histologically
classified according to the WHO classification and staged
according to the tumour node metastasis classification (Sobin
and Fleming, 1997). Overall survival was defined as the period of
time from initial diagnosis to death or last contact, that is, date of
last follow-up visit. Progression-free survival was defined as the
time from surgery with curative intent to appearance of disease
recurrence or evidence of new lesions detected by computed
tomography.
Immunohistochemistry
TROP2 expression was determined by immunohistochemistry
using a purified goat polyclonal antibody detecting the recombi-
nant human TROP2 extracellular domain at a dilution of 1:50
(AF650, R&D Systems, Inc., Minneapolis, MN, USA) as described
earlier (Fong et al, 2008). Colon carcinoma samples with various
TROP2 expression levels (no, low, moderate, or high expression)
were used as positive and negative controls. In addition, 10
samples of normal pancreatic tissue were collected from patients
undergoing pancreatic surgery at Innsbruck Medical University.
TROP2 antigen overexpression was evaluated by two independent
observers (PM and DF) using light microscopy in a blinded
manner. Discordant cases were reevaluated on a double-headed
microscope to achieve a consensus. Antigen expression was
defined as the presence of specific staining on surface membranes
of tumour cells. TROP2 overexpression was evaluated for each
tissue sample by calculating a total immunostaining score as the
product of a proportion and intensity score. The proportion score
described the estimated fraction of positive-stained tumour cells
(0, none; 1, o10%; 2, 10–50%; 3, 51–80%; 4, 480%). The
intensity score represented the estimated staining intensity (0, no
staining; 1, weak; 2, moderate; 3, strong). The total score ranged
from 0 to 12. As described earlier, TROP2 ‘overexpression’
was defined as a total score of more than 4 (Fong et al, 2008).
Representative micrographs of tumours with predominant
membranous staining of TROP2 are shown in Figure 1.
Statistical analysis
Statistical analysis was performed using the Statistical Package
of Social Sciences (SPSS, version 10.0, Chicago, IL, USA).
Correlations between TROP2 expression and clinicopathological
variables were assessed with the w
2-test. Survival rates were
calculated using the Kaplan–Meier method and compared by
means of the log-rank test. Follow-up time was censored if the
patient was lost during follow-up. Factors with prognostic
significance in the univariate models were further evaluated in a
multivariate Cox regression model. For all analyses, a P-value of
less than 0.05 was considered statistically significant.
RESULTS
Patient characteristics
Demographic data and tumour characteristics are summarised in
Table 1. At the time of last clinical follow-up (February 2008), 155
(79%) patients out of the total group had died. Median overall
survival was 9 months (range, 1–68). Most patients (68%) had
undergone primary surgical intervention, whereas 54 (27%)
patients were considered inoperable (9 cases unknown). Palliative
surgery included palliative bypass or endoscopic bile duct stenting.
If indicated, patients received standard gemcitabine-based
chemotherapy according to their clinical stage and performance
status. In 17 patients, exact staging according to UICC was not
feasible.
Immunohistochemistry
As reported earlier, islets of Langerhans displayed no TROP2
staining (Stein et al, 1993a), whereas in normal pancreatic
epithelium TROP2 expression was weak to moderate (Figure 1).
In contrast, moderate-to-strong homogeneous membranous
expression of TROP2 was detected in 109 (55%) of 197 carcinoma
specimens. Strong TROP2 expression (score 9–12) was found in 57
(29%) of 197 cases, moderate expression (score 6–8) in 52 (26%)
cases, weak expression (score 1–4) in 76 (39%) cases and absent
expression (score 0) in 12 (6%) of 197 cases. Thus, according to
our earlier defined criteria (Fong et al, 2008), TROP2 was found to
be overexpressed in 109 (55%) of 197 cases.
Clinicopathological variables and patient survival
Univariate analysis showed TROP2 overexpression to be signifi-
cantly correlated with histologic grading (P¼0.01) and the
presence of lymph node metastases (P¼0.04), but not with sex,
age, T stage, presence of distant metastasis, or involvement of the
resection margin (Table 2). To assess the impact of clinicopatho-
logical features and TROP2 overexpression on survival, we used
Kaplan–Meier analysis and the log-rank test for censored survival
data. Consistent with earlier findings, early tumour stage and a
negative resection margin were associated with longer overall
survival (Table 1). It should be noted that TROP2 overexpression
was significantly correlated with poor overall survival (Po0.01;
Figure 2). Median overall survival time for patients with tumour
presenting with and without TROP2 overexpression was 8 and 14
months, respectively. Overall survival gradually declined with
AB
CD
Figure 1 TROP2 immunostaining in pancreatic tissue, original magnifica-
tion  100. (A) TROP2-negative tumour sample (score 0), normal
pancreatic tissue (arrow) showing weak (score 2) immunostaining.
Pancreatic ductal adenocarcinoma with moderate (score 6) (B) and strong
(score 12) (C and D) TROP2 expression, note the TROP2-negative islets
of Langerhans (arrow).
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sincreasing TROP2 scores. In the subset of patients with tumours
lacking TROP2 overexpression (score 0), median overall survival
time was 15 months and decreased to 14 months (score 1–4), 10
months (score 5–8) and 7 months (score 9–12) with increasing
staining scores. Multivariate analysis identified TROP2 over-
expression together with a negative resection margin as an
independent prognostic factor for poor overall survival
(Table 3a). Subsequently, a detailed analysis for the subgroup of
patients who underwent surgery with curative intent (n¼134) was
performed.
Resected cohort with curative intent
Data on relapse or disease progression were available in 78%
(n¼105) of the patients. Median overall and progression-free
survival was 13 (range, 1–68) months and 6 (range, 1–56) months,
respectively. Survival analyses revealed that TROP2 overexpression
was significantly correlated with poor overall survival (Po0.01;
Figure 3A) as well as a shortened progression-free interval
(Po0.01; Figure 3B). Table 3b shows the multivariate analyses
for patients treated surgically with curative intent. This model was
refined by stepwise removal of variables. Regarding overall
survival, TROP2 overexpression together with a negative resection
margin has been identified to be an independent prognostic
marker. Concerning progression-free survival, TROP2 overexpres-
sion was independent of nodal status and margin involvement by
the tumour.
DISCUSSION
This study describes the prognostic value of TROP2 expression in
pancreatic cancer. Overexpression of TROP2 was detectable in 109
(55%) of 197 tumour samples and was significantly correlated with
decreased overall survival. In multivariate analyses, TROP2
overexpression was shown to be an independent prognostic
biomarker for poor overall survival. Furthermore, TROP2 over-
expression was significantly associated with a shortened progres-
sion-free survival in the subgroup of patients who underwent
surgery with curative intent.
Both cell-surface glycoproteins, TROP2 and EpCAM, are
encoded by the GA733 gene family and have been efficiently
Table 1 Patient characteristics
Pancreatic cancer
Variable (n)( % )
P-value
(log-rank test)
Sex (n¼197)
Male 111 (56) 0.80
Female 86 (44)
Age (n¼197)
Mean 65
Median 67
Range 37–91
T stage (n¼176)
pT1 13 (7) o0.01
pT2 52 (29)
pT3 80 (46)
pT4 31 (18)
Lymph node status (n¼176)
Negative 65 (37) o0.01
Positive 111 (63)
Distant metastasis (n¼142)
No 117 (82) o0.01
Yes 25 (18)
Surgical margin (n¼128)
Negative 86 (67) o0.01
Positive 42 (33)
Stage (UICC) (n¼180)
IA 6 (3) o0.01
IB 24 (13)
IIA 34 (19)
IIB 70 (39)
III 20 (11)
IV 26 (15)
Differentiation (n¼181)
Well 24 (13) 0.07
Moderate 84 (47)
Poor 73 (40)
TROP2 overexpression (n¼197)
Yes 109 (55) o0.01
No 88 (45)
Table 2 Correlation of TROP2 overexpression with conventional
clinicopathological parameters
TROP2 overexpression
No Yes
Total patients (n) n (%) n (%) P-value
Sex (n¼197)
Male 111 51 (46) 60 (54) 0.68
Female 86 37 (43) 49 (57)
Age at diagnosis (n¼197)
o65 years 84 37 (44) 47 (56) 0.88
X65 years 113 51 (45) 62 (55)
Differentiation (n¼181)
Well 24 17 (71) 7 (29) 0.01
Moderate 84 38 (45) 46 (55)
Poor 73 26 (36) 47 (64)
T stage (n¼176)
pT1 13 5 (38) 8 (62) 0.06
pT2 52 27 (52) 25 (48)
pT3 80 36 (45) 44 (55)
pT4 31 7 (23) 24 (77)
Lymph node status (n¼176)
No 65 34 (52) 31 (48) 0.04
Yes 111 41 (37) 70 (63)
Distant metastasis (n¼142)
No 117 56 (48) 61 (52) 0.14
Yes 25 8 (32) 17 (68)
Surgical margin (n¼128)
Negative 86 45 (52) 41 (48) 0.10
Positive 42 16 (38) 26 (62)
Stage (UICC) (n¼180)
IA 6 4 (67) 2 (33) 0.03
IB 24 15 (63) 9 (37)
IIA 34 15 (44) 19 (56)
IIB 70 32 (46) 38 (54)
III 20 3 (15) 17 (85)
IV 26 9 (35) 17 (64)
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stargeted by monoclonal antibodies in vitro as well as in vivo
(Velders et al, 1998; Ruan et al, 2003; Wang et al, 2008). Similarly
TROP2, EpCAM overexpression was also found to be a strong
prognostic marker for poor survival in various epithelial cancer
entities (Gastl et al, 2000; Varga et al, 2004; Stoecklein et al, 2006).
Owing to its immunogenic properties in cancer patients, active and
passive immunotherapeutic agents against the EpCAM antigen
have been developed (Riethmuller et al, 1998; de Bono et al, 2004).
The functional role of TROP2 in carcinogenesis and tumour
progression is only poorly understood. Fornaro et al (1995), who
first cloned the human TROP2 gene, speculated that TROP2 might
be a cell-surface signal transducer and might regulate tumour cell
proliferation. This assumption is substantiated by the finding that
the cytoplasmic domain of TROP2 contains several potential
phosphorylation sites and TROP2 cross-linking antibodies can
cause a transient increase in intracellular calcium levels (Basu et al,
1995; Ripani et al, 1998). Moreover, it has been shown that human
cancer cells can express an oncogenic hybrid mRNA between
TROP2 and cyclin D1, a master regulator of the cell cycle
(Terrinoni et al, 2001). Interestingly, TROP2 seems to be involved
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Figure 2 Prognostic significance of TROP2 antigen expression in 197
patients with pancreatic ductal adenocarcinomas regarding overall survival
as calculated by Kaplan–Meier analysis. Low, patients with tumour (n¼88)
without TROP2 overexpression; high, patients with tumour (n¼109) with
TROP2 overexpression. Patients with low TROP2 expression had
significantly better overall survival than patients with high TROP2
expression as defined by the log-rank test (Po0.01).
Table 3 Multivariate analyses (Cox regression) of various prognostic
parameters in the total cohort and subgroup of patients with curative intent
Overall survival
P-value RR 95% CI
(a) Total group of patients (n¼197)
T stage 0.81 1.0 0.7–1.4
Nodal status 0.94 0.9 0.5–1.6
Distant metastasis 0.71 0.7 0.1–5.2
Surgical margin 0.02 1.9 1.1–3.5
TROP2 overexpression 0.01 1.8 1.1–3.1
Progression-free
survival
Overall
survival
P-value RR 95% CI P-value RR 95% CI
(b) Subgroup of patients treated surgically with curative intent (n¼134)
T stage 0.720 0.9 0.6–1.3 0.721 0.9 0.6–1.3
Nodal status 0.545 1.1 0.6–2.1 0.764 0.9 0.5–1.5
Surgical margin 0.276 1.4 0.7–2.7 0.012 2.0 1.1–3.5
TROP2 overexpression 0.070 1.6 0.9–2.8 0.009 1.8 1.1–3.0
Nodal status 0.562 1.1 0.6–2.1 0.772 0.9 0.5–1.5
Surgical margin 0.301 1.3 0.7–2.6 0.012 1.9 1.1–3.3
TROP2 overexpression 0.073 1.6 0.9–2.7 0.009 1.8 1.1–3.0
Surgical margin 0.185 1.4 0.8–2.7 0.009 1.9 1.1–3.1
TROP2 overexpression 0.053 1.6 0.9–2.8 0.009 1.8 1.1–2.9
Nodal status 0.193 1.3 0.8–2.2 0.288 1.2 0.8–1.9
TROP2 overexpression 0.014 1.8 1.1–2.9 0.000 2.0 1.3–3.1
Abbreviations: CI¼confidence Interval; RR¼relative risk.
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Figure 3 Prognostic significance of TROP2 antigen expression in the
subgroup of patients who underwent surgery with curative intent regarding
overall (n¼134) and progression-free (n¼105) survival as calculated by
Kaplan–Meier analysis. Patients with tumour tissue presenting TROP2
overexpression (TROP2 high) had a significant shortened overall survival
(A) and progression-free (B) interval as compared with patients with
tumours lacking TROP2 overexpression (TROP2 low).
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sin regulating the shift between cell migration and differentiation in
primordium cells (Villablanca et al, 2006). However, its physio-
logical ligand is still unknown. Schon et al (1993) were able to
demonstrate that EpCAM can undergo proteolytic processing and
that cleavage may activate EpCAM signalling. Similar mechanisms
have been hypothesised for TROP2 (Fornaro et al, 1995). Recently,
TROP2 expression was shown to correlate with invasive tumour
phenotypes and poor prognosis (Ohmachi et al, 2006; Fong et al,
2008). In pancreatic cancer, TROP2 was previously reported to be
highly expressed (Iacobuzio-Donahue et al, 2002), whereas Wang
et al (2008) identified TROP2 as an oncogene and a potential
therapeutic target in colon cancer. In fact, blocking experiments
with anti-TROP2 antibodies revealed that TROP2 can contribute to
tumour cell migration and invasion. Moreover, increasing TROP2
expression prompted an anchorage-independent growth of colon
cancer cells.
The murine monoclonal antibody (mAb) RS7 reacts specifically
with TROP2 and exhibits functional properties that make it an
attractive tool for clinical diagnostic and therapeutic applications
(Stein et al, 2003b). Indeed, radiolabelled RS7 has been applied for
tumour imaging and revealed significant antitumour activity in
several animal models (Shih et al, 1995; Stein et al, 1999c).
Meanwhile, RS7 was successfully humanised and showed promis-
ing antitumour effects in an in vivo breast cancer model (Govindan
et al, 2004).
In conclusion, we have demonstrated that TROP2 is a novel
prognostic biomarker for pancreatic adenocarcinoma. These data
must be confirmed and validated prospectively. Furthermore,
TROP2 harbours the potential to become an attractive target
for antibody-based therapies for the subset of patients with
TROP2-overexpressing pancreatic cancer.
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